Atai Life Sciences N.V. (ATAI)

Jan 16, 2026, 7:00 AM EST - 18 days ago

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation

Jan 8, 2026, 7:00 AM EST - 26 days ago

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

Dec 23, 2025, 7:00 AM EST - 6 weeks ago

AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

Nov 19, 2025, 7:32 PM EST - 2 months ago

Enhanced Fortifies Executive Leadership Team & Board of Directors

Nov 11, 2025, 9:21 AM EST - 3 months ago

Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression Transcript

Oct 20, 2025, 5:29 PM EDT - 3 months ago

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

Oct 20, 2025, 9:00 AM EDT - 3 months ago

Atai Life Sciences And Beckley Psytech: Promising Emerging Leader In Psychedelics

Oct 16, 2025, 10:31 PM EDT - 3 months ago

atai Life Sciences Announces Pricing of Public Offering of Common Shares

Oct 16, 2025, 4:12 PM EDT - 3 months ago

atai Life Sciences Announces Proposed Public Offering of Common Shares

Oct 16, 2025, 4:10 PM EDT - 3 months ago

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

Oct 13, 2025, 2:21 PM EDT - 4 months ago

Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside

Oct 1, 2025, 2:40 PM EDT - 4 months ago

Atai Life Sciences: Still A Decent Prospect - But Only Just

Sep 23, 2025, 2:50 PM EDT - 4 months ago

Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients

Sep 23, 2025, 7:00 AM EDT - 4 months ago

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

Sep 9, 2025, 6:59 AM EDT - 5 months ago

Atai Life Sciences N.V. (ATAI) Presents at H.C.

Aug 28, 2025, 4:05 PM EDT - 5 months ago

atai Life Sciences to Participate in September Investor Conferences

Jul 28, 2025, 5:01 PM EDT - 6 months ago

Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus

Jul 28, 2025, 10:58 AM EDT - 6 months ago

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

Jul 28, 2025, 8:13 AM EDT - 6 months ago

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

RVTY

Jul 25, 2025, 4:16 PM EDT - 6 months ago

Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial

Jul 25, 2025, 4:05 PM EDT - 6 months ago

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Jul 2, 2025, 2:29 PM EDT - 7 months ago

Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD

Jul 1, 2025, 9:28 AM EDT - 7 months ago

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

Jul 1, 2025, 6:05 AM EDT - 7 months ago

atai Life Sciences Announces $50 Million Private Placement Financing

Jul 1, 2025, 6:00 AM EDT - 7 months ago

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

Jun 2, 2025, 6:00 AM EDT - 8 months ago

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

May 29, 2025, 8:30 AM EDT - 8 months ago

atai Life Sciences to Participate in Upcoming Investor Conferences

May 20, 2025, 7:00 AM EDT - 9 months ago

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

May 14, 2025, 7:00 AM EDT - 9 months ago

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 13, 2025, 7:01 AM EDT - 9 months ago

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

Mar 11, 2025, 7:00 AM EDT - 11 months ago

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

Feb 27, 2025, 12:45 PM EST - 1 year ago

Atai: Following The Path That Spravato Laid And Moving Beyond It

Feb 24, 2025, 4:10 PM EST - 1 year ago

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

Jan 29, 2025, 11:57 AM EST - 1 year ago

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

Jan 10, 2025, 7:00 AM EST - 1 year ago

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

Oct 2, 2024, 9:21 AM EDT - 1 year ago

IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG

Sep 4, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 2:00 PM EDT - 1 year ago

Psychedelic Stock Deep Dive: Atai Life Sciences

Aug 13, 2024, 7:10 AM EDT - 1 year ago

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 12, 2024, 12:12 PM EDT - 1 year ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

CMPS DFTX

Aug 7, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

Jun 26, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

Jun 20, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

May 31, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

May 15, 2024, 6:59 AM EDT - 1 year ago

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

Apr 24, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

Apr 17, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Mar 28, 2024, 7:00 AM EDT - 2 years ago

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

Mar 27, 2024, 7:00 AM EDT - 2 years ago

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression